Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Graham

Showing results (141-150 of 166) with videos related to

Pageof 17
Sort By:
American Heart Journal|March 9, 2023
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning methodChe Ngufor, Xiaoxi Yao, Jonathan W Inselman, et al.
Circulation|November 1, 2014
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillationDavid J Graham, Marsha E Reichman, Michael Wernecke, et al.
The American Journal of Psychiatry|June 15, 2022
Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare BeneficiariesAndrew D Mosholder, Yong Ma, Sandia Akhtar, et al.
The American Journal of Medicine|January 15, 2019
Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial FibrillationDavid J Graham, Elande Baro, Rongmei Zhang, et al.
Annals of Internal Medicine|April 26, 2016
Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort StudySengwee Toh, Christian Hampp, Marsha E Reichman, et al.
JAMA Internal Medicine|October 4, 2016
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial FibrillationDavid J Graham, Marsha E Reichman, Michael Wernecke, et al.
Journal of General Internal Medicine|November 25, 2024
Antipsychotics and Risk of Acute Respiratory Failure in U.S. Medicare Beneficiaries with Chronic Obstructive Pulmonary DiseaseSilvia Perez-Vilar, Andrew D Mosholder, Elizabeth R Smith, et al.
The Journal of Clinical Endocrinology and Metabolism|January 29, 2019
Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016Joseph S Ross, Stefanie Rohde, Lindsey Sangaralingham, et al.
Annals of Internal Medicine|November 14, 2017
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort StudyAlan S Go, Daniel E Singer, Sengwee Toh, et al.
Pharmacotherapy|October 19, 2024
Use of proton pump inhibitors and risk of severe COVID-19: A case-control study in United States Medicare beneficiariesAndrew D Mosholder, Hector S Izurieta, Rongmei Zhang, et al.
Pageof 17

Showing results (141-150 of 166) with videos related to

Sort By:
Pageof 17
American Heart Journal|March 9, 2023
Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning methodChe Ngufor, Xiaoxi Yao, Jonathan W Inselman, et al.
Circulation|November 1, 2014
Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillationDavid J Graham, Marsha E Reichman, Michael Wernecke, et al.
The American Journal of Psychiatry|June 15, 2022
Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare BeneficiariesAndrew D Mosholder, Yong Ma, Sandia Akhtar, et al.
The American Journal of Medicine|January 15, 2019
Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial FibrillationDavid J Graham, Elande Baro, Rongmei Zhang, et al.
Annals of Internal Medicine|April 26, 2016
Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort StudySengwee Toh, Christian Hampp, Marsha E Reichman, et al.
JAMA Internal Medicine|October 4, 2016
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial FibrillationDavid J Graham, Marsha E Reichman, Michael Wernecke, et al.
Journal of General Internal Medicine|November 25, 2024
Antipsychotics and Risk of Acute Respiratory Failure in U.S. Medicare Beneficiaries with Chronic Obstructive Pulmonary DiseaseSilvia Perez-Vilar, Andrew D Mosholder, Elizabeth R Smith, et al.
The Journal of Clinical Endocrinology and Metabolism|January 29, 2019
Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016Joseph S Ross, Stefanie Rohde, Lindsey Sangaralingham, et al.
Annals of Internal Medicine|November 14, 2017
Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort StudyAlan S Go, Daniel E Singer, Sengwee Toh, et al.
Pharmacotherapy|October 19, 2024
Use of proton pump inhibitors and risk of severe COVID-19: A case-control study in United States Medicare beneficiariesAndrew D Mosholder, Hector S Izurieta, Rongmei Zhang, et al.
Pageof 17